JDJagadish Babu Dasari

Jagadish Babu Dasari

*This is an algorithmically generated author record based on publicly available information.

Jagadish Babu Dasari has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Bini Chhetri Soren

    Department of Research and Development, Quanton BioLife Sciences, Ghatsila, Jharkhand, India

    4 shared publications
  • Paola Fiorani

    Department of Biology, University of Rome Tor Vergata, Via della Ricerca Scientifica, 00133 Rome, Italy

    3 shared publications
  • Alessio Ottaviani

    Department of Biology, University of Rome Tor Vergata, Via della Ricerca Scientifica 1, 00133 Rome, Italy

    2 shared publications
  • Beatrice Messina

    Department of Biology, University of Rome Tor Vergata, Via della Ricerca Scientifica 1, 00133 Rome, Italy

    2 shared publications
  • Syed Junied

    Department of Research and Development, Quanton BioLife Sciences, Ghatsila, Jharkhand, India

    2 shared publications
  • A. Intorcia

    Univ Roma Tor Vergata, Div Cardiol, Rome, Italy

    1 shared publication

Latest Publications

  • Mechanistic Insights into the Inhibition of Plasmodium falciparum DNA Gyrase A by Withanolide Derivatives through Integrated Computational Analysis

    by Bini Chhetri Soren, Soujanya J. Vastrad, Syed Junied, Diya Srikanth, Aparna Chimalamari, Bj Mahender Kumar Jayappa, Jagadish Babu Dasari

    Introduction: Malaria is a fatal disease affecting millions of people worldwide, primarily due to infection by Plasmodium falciparum. The emergence of multidrug-resistant parasite strains has necessitated the exploration of novel therapeutic targets. Plasmodium falciparum DNA gyrase A (pfDNA gyrase A), an essential topoisomerase II that is not present in humans, is a promising antimalarial drug target. This study explores the inhibitory potential of three Withania somnifera withanolide derivatives, D, E, and O, against pfDNA gyrase A Methods: An integrated structure-based computational analysis was conducted to explore the inhibitory potential of three withanolides (D, E, and O) against pfDNA gyrase A. Molecular docking, Molecular Dynamics (MD) simulations, and Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) free energy calculations were performed. Pharmacokinetic properties were analysed using SWISS ADME and pkCSM tools. Results: Molecular docking revealed high binding affinities for withanolide D (-9.14kcal/mol), E (-9.73kcal/mol), and O (-9.00kcal/mol), with interactions mediated through key catalytic residues, such as GLU648, LYS647, and TRY590, via hydrogen bonding and hydrophobic contacts. MD simulations confirmed the structural integrity and compactness of the complexes through Root Mean Square Deviation (RMSD), Root Mean Square Fluctuation (RMSF), Radius of Gyration (Rg), and Solvent Accessible Surface Area (SASA). MM/GBSA calculations are further supported by showing the lowest binding free energy for withanolide O and E (ΔGbind =-20.89 and -20.22 kcal/mol). The ADME studies showed favourable pharmacokinetic and physicochemical properties Discussion: This study identifies pfDNA gyrase A as a potential molecular target of Withania somnifera-derived withanolides and elucidates their inhibitory mechanism. Withanolides O and E exhibited strong binding affinity, favorable energetics, and distinct dynamic effects, acting through activesite occlusion and allosteric modulation, respectively. Molecular dynamics and free-energy analyses suggest that effective inhibition results from both structural stabilization and the disruption of critical enzyme motions. Conclusion: Withanolide derivatives were identified as promising inhibitors of pfDNA gyrase A, highlighting their potential as antimalarial agents for addressing drug-resistant malaria.

    • 1 January 2020
      • Vol. 8  (4) , 366-375

    Swapping of The N-Terminal Domain of Human Topoisomerase 1B with the Corresponding Plasmodium Falciparum Counterpart Strongly Impairs Enzyme Activity

    by Jagadish Babu Dasari, Bini Chhetri Soren, Alessio Ottaviani, Cinzia Tesauro, Simona Marino, Beatrice Messina, Paola Fiorani

    Background: DNA topoisomerases 1B are a class of ubiquitous enzyme that solves the topological problems associated with biological processes such as replication, transcription and recombination. Numerous sequence alignment of topoisomerase 1B from different species shows that the lengths of different domains as well as their amino acids sequences are quite different. In the present study a hybrid enzyme, generated by swapping the N-terminal of Plasmodium falciparum into the corresponding domain of the human, has been characterized. Methods: The chimeric enzyme was generated using different sets of PCR. The in vitro characterization was carried out using different DNA substrate including radio-labelled oligonucleotides. Results: The chimeric enzyme displayed slower relaxation activity, cleavage and re-ligation kinetics strongly perturbed when compared to the human enzyme. Conclusions: These results indicate that the N-terminal domain has a crucial role in modulating topoisomerase activity in different species.

  • The human DNA topoisomerase I mutant Gly717Asp: Higher religation rate is not always associated with camptothecin resistance

    by Zhenxing Wang, Ilda D'ANnessa, Cinzia Tesauro, Alessio Ottaviani, Bini Chhetri Soren, Jagadish Babu Dasari, Beatrice Messina, Anil Thareparambil, Paola Fiorani

  • Open Access

    Topoisomerase IB: a relaxing enzyme for stressed DNA

    by Bini Chhetri Soren, Jagadish Babu Dasari, Alessio Ottaviani, Federico Lacovelli, Paola Fiorani

    Cancer Drug Resistance is an open access journal, focusing on pharmacological aspects of drug resistance and its reversal, molecular mechanisms of drug resistance and drug classes, etc. Both clinical and experimental aspects of drug resistance in cancer are included.


    • 1 December 2018
      • Vol. 22  (23) , 8502-8508

    Efficacy and safety of dronedarone in patients with amiodarone-induced hyperthyroidism: a clinical study

    by M. A. Perrone, J. Babu Dasari, A. Intorcia, R. Morgagni, D. Sergi, F. Battaini, A. De Lorenzo, S. Bernardini, G. Merra, F. Romeo

    OBJECTIVE: The aim of the study was to examine the safety and efficacy of dronedarone in patients with a history of atrial fibrillation and amiodarone-induced hyperthyroidism. PATIENTS AND METHODS: We conducted a prospective study to evaluate the use of amiodarone and dronedarone in 124 patients with a history of paroxysmal atrial fibrillation who had no additional structural heart disease. All patients received amiodarone 200 mg qd. Out of 124 patients, 56 (45%) switched to dronedarone 400 mg bid due to amiodarone-induced hyperthyroidism and the remaining 68 patients (55%), with normal thyroid function, continued to receive amiodarone. The follow-up period was 12 months, and the patients were regularly monitored. RESULTS: The primary outcome after 6 months dronedarone and amiodarone group was 56 and 68. including 38 (68%) and 54 (79.4%) (Odds ratio [OR] = 1.17, 95% confidence interval [95% CI] = 0.68-2.02) patients with sinus rhythm (SR) and 18 (32.14%) and 14 (28.6%) (odds ratio [OR] = 0.64, confidence interval [95% CI] = 0.29-1.40) patients with atrial fibrillation (AF). The secondary outcome after 12 months showed significant difference in thyroid function in the dronedarone group. Out of 46 patients, 24 (56.18%) patients reduced hyperthyroidism compared to the amiodarone group: out of 68, 6 (8.9%) patients were observed to have hyperthyroidism. At 12 months, there were 24 (43%) and 22 (62%) (odds ratio [OR] = 0.75, confidence interval [95% CI] = 0.38-1.49) patients with SR, and 32 (57%) and 26 (38%) (odds ratio [OR] = 0.67, confidence interval [95% CI] = 0.36-1.25) patients with AF. CONCLUSIONS: In our study, dronedarone appears to be a good therapeutic option in the treatment of atrial fibrillation in patients with amiodarone-induced hyperthyroidism. However. long-term studies are needed to estimate the efficacy and toxicity of both drugs.


  • Open Access

    Impact of Microbial Culture Analysis and Prophylactic use of Antibiotics in Acute Severe Pancreatitis

    by Jagadish Babu Dasari, Cristiano Ialongo, Aruna Chandranath Kondakundhi, Sri Harsha Munnamgi, Syed Juied